Member Info for Krone

Endpoints reports adverse effects in teen studies. On the face of it this bodes well for Sareum.
https://endpts.com/pfizer-offers-3rd-round-of-jak-data-this-time-in-kids-can-it-compete/

Perhaps a change of broker to a more dynamic and upbeat outfit would spur some life into this old dog?

Thanks Basil, nice post. They don’t need external advice, they’ve got Stephen Parker on board. Stephen is an expert in corporate finance and institutional investors.....at least that’s what his profile says!

http://www.sareum.com/files/2415/9161/5348/TimMitchell-Sareum_BIO_Digital_2020.pdf
Slide 10 indicates SDC1801 against cancer idications.
The word FUNDING - is hanging at the bottom of the slide with no corresponding text...
It really is about time Stephen Parker grabbed this by the short and curlies. We are expected to belive that this will imminently be a multi billion pound company. At this crucial juncture it is entirely reasonable to expect that the shop window is glistening to perfection.

Pretty much the same slides as April Biotrinity.

RMM - yes very nerve wracking. Kellie Fredericks was acting for Sareum at the last hearing so is familiar with the issues. The transcript of the last hearing is somewhere on the patent office website. It is hellishly complex to the layman. It would appear that we are in good hands.

The call will be between Kellie Fredericks patent lawyer acting for Sareum and the Patent Office.

Hi Fadec - at today's rates a 55% stake in Sareum would cost approximately £8m.

These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.
https://immunology.sciencemag.org/content/5/48/eabd0110.full

Hi Fadec, nice find and surely pertinent 1801/2 in the Covid context...

https://youtu.be/ouYKeeTz7Yw

Is that a buy?

Thoth - and that the results would be published 'in the near future'.

So Glover has gone...but not quite....
https://newsfilter.io/a/7b573f44f5c6802f8d7f42617c622cd4

For a $7.3m golden hello one would expect Stephen Dilly to make some prompt and decisive changes to sort out the mess left by Glover, including SRA737!

Note, applications, plural.
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "We believe that our TYK2/JAK1 inhibitor candidates - SDC-1801 and SDC-1802 - represent exciting prospects. The way they act continues to be a focus for the broader industry interested in treating autoimmune diseases, cancer and more recently in addressing the severe respiratory symptoms associated with advanced COVID-19. These new funds will be used to advance their preclinical studies targeting completion in at least one indication late this year, pending successful progress. In addition, we will be making applications for grant funding to investigate their potential in COVID-19. Our aim is to generate an attractive data package for both compounds that will support our dialogue with potential partners.

Further background re hyper-inflammatory response in Covid19.
https://www.medrxiv.org/content/10.1101/2020.05.28.20115758v1
‘Importantly, when adjusting for disease severity score, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-a serum levels remained independent and significant predictors of disease severity and death. We propose that serum IL-6 and TNF-a levels should be considered in the management and treatment of COVID-19 patients to stratify prospective clinical trials, guide resource allocation and inform therapeutic options. We also propose that patients with high IL-6 and TNF-a levels should be assessed for combinatorial blockade of pathogenic inflammation in this disease’.

One step forwards... - Remdesivir delivers another perverse result
https://twitter.com/sparksinsurrey/status/1267482540782354433?s=21

Hi Minden - simply highlighting what we already know I suppose know in terms of the trials activity in the Covid space. When the Sareum grant in respect of SRA1801 is confirmed hopefully we'll get some high profile PR.

https://www.theguardian.com/world/2020/jun/01/uk-hospitals-trial-five-new-drugs-search-coronavirus-treatment?CMP=Share_iOSApp_Other